Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Prognostic Value of the Expression of Programmed Death Ligand 1 (PD-L1) in Early Stage Non-small-cell Lung Cancer

NCT03078959 is registered in ClinicalTrials.gov with Fondazione Ricerca Traslazionale as lead sponsor.

NCT NCT03078959
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03078959 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Prognostic Value of the Expression of Programmed Death Ligand 1 (PD-L1) in Early Stage Non-small-cell Lung Cancer
Lead sponsor
Fondazione Ricerca Traslazionale
Phase
Observational
Overall status
Unknown status
Start date
March 3, 2017
Completion date
April 15, 2017
Enrollment
350 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung